Ethical Values in the
Treatment of Depression and
JOHN LILJA1, SAM LARSSON2, DAVID HAMILTON3 AND MIA BAUER4
1Department of Biochemistry and Pharmacy, Abo Academy University,
Turku, Finland 2Department of Social Work, University of Stockholm and
Karolinska Institute, Center for Dependency Disorders, Magnus Huss Clinic,
Stockholm, Sweden 3Department of Adult and Continuing Education,
University of Glasgow, Glasgow, UK 4Statoil, Bergen, Norway
In any analysis of depression and anxiety these conditions can be viewed from several different perspectives. In this chapter we restrict our analysis to four different perspectives: biological, interactional, flow and symptom. The selection of any of the four has a number of implications in terms of the recommended type of treatment, treatment goals and the ways in which it is determined whether or not these goals have been achieved.
The four perspectives are often combined. However, it is necessary to look at the perspectives individually if our task is to analyse how prescribes and patients combine the different perspectives.
There has been intensive debate about the new antidepressants. Arguments and counter arguments reflect different ethical values regarding depression and anxiety. For those who have a restrictive attitude to the use of drugs, personal difficulties like divorce or the death of a family member should be handled by psychosocial coping strategies. The main counter argument is that
Pharmaceutical Ethics. Edited by S. Salek and A. Edgar. © 2002 John Wiley & Sons, Ltd.